神经内分泌前列腺癌 (NEPC) 是一种罕见且具有侵袭性的前列腺癌 (PCa) 亚型，采用先进治疗方法出现，其特点是雄激素受体 (AR) 信号传导和神经内分泌特征丧失，从而导致快速进展和治疗耐药。第三届治疗引起的 NEPC 研讨会于 2024 年 6 月 21 日至 23 日在加拿大不列颠哥伦比亚省哈里森温泉度假村举行，全球领先的研究人员和临床医生齐聚一堂。该活动由温哥华前列腺中心 (VPC)、加拿大健康研究所、加拿大前列腺癌基金会和 Pharma Planter Inc 赞助，重点关注最新的 NEPC 研究和创新治疗策略。由博士共同主持。在王玉卓和 Martin Gleave 的主持下，研讨会的主题是 NEPC 的历史背景、分子途径、表观遗传调控以及肿瘤微环境和代谢在其进展中的作用。 Himisha Beltran 博士和 Martin Gleave 博士等专家的主题演讲强调了 NEPC 的复杂性。新兴人才会议展示了新的研究，指出了 NEPC 治疗的未来。研讨会最终就需要早期检测、靶向治疗和个性化医疗以有效对抗 NEPC 达成共识，并强调全球合作在推进 NEPC 理解和治疗方面的重要性。

Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features, leading to rapid progression and treatment resistance. The third symposium on treatment-induced NEPC, held from 21 to 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united leading global researchers and clinicians. Sponsored by the Vancouver Prostate Centre (VPC), Canadian Institute of Health Research, Prostate Cancer Foundation Canada and Pharma Planter Inc, the event focused on the latest NEPC research and innovative treatment strategies. Co-chaired by Drs. Yuzhuo Wang and Martin Gleave, the symposium featured sessions on NEPC's historical context, molecular pathways, epigenetic regulation and the role of the tumor microenvironment and metabolism in its progression. Keynotes from experts like Dr. Himisha Beltran and Dr. Martin Gleave highlighted the complexity of NEPC. The Emerging Talent session showcased new research, pointing to the future of NEPC treatment. The symposium concluded with a consensus on the need for early detection, targeted therapies and personalized medicine to effectively combat NEPC, emphasizing the importance of global collaboration in advancing NEPC understanding and treatment.